Prostate cancer trials in Netherlands

In Netherlands 69 Also abroad 1481

69 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Not yet taking people in Netherlands
A clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
Where
Maastricht, Nijmegen
Age
18 years and over
People
47 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-512340-32-01 · EU 2024-512340-32-01
Phase 1/2Not yet taking people in Netherlands
[89Zr]Zr-PSMA-N139 PET/CT imaging in primary and recurrent prostate cancer.
Where
Nijmegen
Age
18 years and over
People
20
Run by
Radboud universitair medisch centrum Stichting
See details and how to join2025-523745-10-00 · EU 2025-523745-10-00
Phase 1/2Taking people
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Where
Amsterdam, Nijmegen
Age
18 years and over
People
54 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07332455
No phaseTaking people
Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions
Where
Amsterdam
Age
18 years and over
People
54
Run by
The Netherlands Cancer Institute
See details and how to joinNCT07391982
Phase 3Taking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Amersfoort, Amsterdam, Heerlen, Hoofddorp, Leeuwarden, Nijmegen, Rotterdam, 's-Gravenhage, Tilburg, Venlo
Age
18 years and over
People
1,310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
Phase 3Taking people
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Where
Nijmegen
Age
18 years and over
People
434 worldwide
Run by
ABX advanced biochemical compounds GmbH
See details and how to joinNCT06122584
Phase 1Not yet taking people in Netherlands
A clinical trial of MK-1568 in participants with prostate cancer (MK-1568-001)
Where
Amsterdam, Nijmegen
Age
18 years and over
People
15
Run by
Merck Sharp & Dohme LLC
See details and how to join2026-526983-19-00 · EU 2026-526983-19-00
Phase 1Taking people
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Where
Rotterdam
Age
18 years and over
People
355 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06095089 · EU 2023-504063-17-00
Phase 3Taking people
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Delft, Groningen, Hilversum, Hoofddorp, Maastricht, Nijmegen, Rotterdam, Zwolle
Age
18 years and over
People
1,203 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00
Phase 3Taking people
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Where
Amsterdam, Leeuwarden, Nijmegen, Schiedam
Age
18 years and over
People
900 worldwide
Run by
Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00
Phase 3Taking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Almelo, Amersfoort, Amsterdam, Groningen, Hilversum, Hoofddorp, Maastricht, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage, Venlo
Age
18 years and over
People
1,440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
No phaseTaking people
The BALANCE Study: BlAck and Mixed Men's Lived Experience With Prostate cANCEr-Diversity in Prostate Cancer PROMS Study
Where
Rotterdam
Age
18 years and over
People
800
Run by
Institute of Cancer Research, United Kingdom
See details and how to joinNCT07529418
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Amsterdam, Groningen, Leiden, Maastricht, Nijmegen
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Amsterdam
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 2Taking people
Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS)
Where
Amsterdam
Age
18 years and over
People
153
Run by
Netherlands Cancer Institute
See details and how to joinNCT06279130 · EU 2023-505756-21-00
Phase 3Taking people
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Groningen
Age
18 years and over
People
750 worldwide
Run by
Amgen
See details and how to joinNCT07213674
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Amsterdam, Nijmegen
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Hilversum, Maastricht, Nijmegen, Roosendaal
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Amsterdam, Delft, Hilversum, Nijmegen
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Drachten, Ede Gld, Nijmegen
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 3Taking people
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Groningen
Age
18 years and over
People
297 worldwide
Run by
Amgen Inc.
See details and how to join2025-520555-89-00 · EU 2025-520555-89-00
No phaseTaking people
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Where
Groningen
Age
18 years and over
People
850 worldwide
Run by
XEOS Medical
See details and how to joinNCT06970275
Phase 2Taking people
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
Where
Rotterdam
Age
18 years and over
People
245
Run by
Erasmus Medical Center
See details and how to joinNCT05762536
No phaseTaking people
Prospective Prostate Cancer Infrastructure
Where
Nijmegen
Age
18 years and over
People
700
Run by
Radboud University Medical Center
See details and how to joinNCT07560748
Phase 3Taking people
[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer
Where
Nijmegen
Age
18 years and over
People
355 worldwide
Run by
Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
See details and how to join2023-504026-19-01 · EU 2023-504026-19-01